New Centre of Excellence brings advanced robotic platforms and multidisciplinary expertise under one roof to expand access to precision-led minimally invasive surgery
As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%
Suven has already begun planning a global Phase 3 registrational program for MDD based on the results
Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion
Indian Pharmacopoeia Commission hosts scientific conclave to brainstorm on strengthening pharmaceutical quality and compliance
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
Chennai based Bioneemtec India has received support from Technology Development Board for commercializing indigenous green chemistry technologies to produce critical pharmaceutical ingredients
Specialised clinic to offer regular device monitoring, battery assessment, rhythm evaluation, and expert cardiac electrophysiology consultation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
